上海交通大学医学院分子医学研究院新建于2017年10月，由中国科学院院士谭蔚泓教授领衔建立，并依托上海交通大学医学院附属仁济医院实体建设。研究院聚焦分子医学前沿，立足于重大疾病创新药物研发与早诊确诊防控技术的突破，从基础前沿研究到知识产权和产业化落地，全程助推健康中国建设。研究院建有上海市核酸化学与纳米医学重点实验室平台，并集聚多名中国科学院院士、国家杰青、国家优青、青年长江学者、国家及上海市高层次引进计划获得者等高水平中青年专家。研究院已经成为学科交叉特色鲜明的教学、科研、产业化人才 “摇篮”。
研究院青年人才聚集，提倡自由学术探索，以学术兴趣和创新潜力为动力，积极鼓励跨学科合作与创新。经团队共同建设，研究院已形成“仁爱互助”、“快乐科研”、“争锋前沿”的文化氛围。目前，设立有核酸化学研究组、分子自组装与分子网络研究组、体外检测与诊断研究组、分子和纳米药物的临床转化等课题组。众多相关成果在Nature、science和Nature 系列等国际知名杂志上发表。近5年团队成员承担有国家重大科学研究计划、科技部重大专项、科技部重大仪器专项、国家杰青、优青基金等多项国家和省部级项目。2019年底，经上海市科委审批研究院正式启动“上海市核酸化学与纳米医学重点实验室”的建设工作。
研究院的实验平台布局合理，技术力量雄厚，仪器设备先进。配备有共聚焦扫描显微镜、轨道阱质谱仪、核磁共振仪、透射电镜、原子力显微镜、紫外光刻系统等多台大型精密仪器。
建院以来，研究院致力完善从基础研究到应用开发的完整创新成果产出。已与上海市三级甲等医疗单位开展临床合作研究，实现了基础研究和临床应用的紧密结合。

Institute of Molecular Medicine, School of Medicine, Shanghai Jiao Tong University, was founded in October 2017 by Prof. Tan Weihong, academician of Chinese Academy of Sciences, and is based on renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Focusing on the frontier of molecular medicine, the Institute is based on the breakthrough of innovative medicine research and development of major diseases and early diagnosis and prevention and control technology. From basic frontier research to the implementation of intellectual property rights and industrialization, the whole process promotes the construction of healthy China. The Institute has established the Shanghai Key Laboratory of Nucleic Acid Chemistry and Nanomaterials, and has gathered many high-level young and middle-aged experts, such as academicians of Chinese Academy of Sciences, National Outstanding Young Scholars, National Outstanding Young scholars, Young Changjiang Scholars, and winners of national and Shanghai High-level Introduction Plan. The institute has become a cradle of talents for teaching, scientific research and industrialization with distinctive interdisciplinary features.
The academy encourages young talents to gather, promotes free academic exploration, and actively encourages interdisciplinary cooperation and innovation driven by academic interest and innovation potential. Through the joint construction of the team, the institute has formed a cultural atmosphere of "benevolence and mutual assistance", "happy scientific research" and "striving for the forefront". At present, there are several research groups, including nuclear acidification research group, molecular self-assembly and molecular network research group, in vitro detection and diagnosis research group, and clinical transformation of molecular and nano drugs. Many related results have been published in Nature, Science and Nature series. In the past five years, our team members have undertaken a number of national and provincial projects, such as national Major scientific research Program, major special projects of the Ministry of Science and Technology, major instrument special projects of the Ministry of Science and Technology, National Outstanding Youth Fund, Excellent Youth Fund and so on. At the end of 2019, the Shanghai Institute of Science and Technology officially launched the construction of "Shanghai Key Laboratory of Nucleic Acid Chemistry and Nanomedicine".
The experimental platform layout of the institute is reasonable, with strong technical force and advanced instruments. Equipped with confocal scanning microscope, orbital well mass spectrometer, nuclear magnetic resonance instrument, transmission electron microscope, atomic force microscope, UV lithography system and other large precision instruments.
Since its establishment, the Institute has been committed to improving the complete output of innovative results from basic research to application development. It has carried out clinical cooperative research with Shanghai Third-class A medical units, realizing the close combination of basic research and clinical application.